Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $106.20 Consensus Price Target from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been assigned a consensus rating of “Hold” from the twenty-two analysts that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $106.20.

ZBH has been the topic of a number of recent research reports. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Tuesday, February 10th. Wall Street Zen cut Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. BTIG Research reiterated a “neutral” rating on shares of Zimmer Biomet in a report on Monday, March 23rd. The Goldman Sachs Group cut Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 target price on the stock. in a report on Friday, January 9th. Finally, TD Cowen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Monday, January 26th.

Zimmer Biomet Price Performance

Shares of ZBH opened at $90.99 on Tuesday. Zimmer Biomet has a 12-month low of $84.59 and a 12-month high of $108.51. The business’s fifty day moving average is $92.40 and its 200 day moving average is $93.55. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The stock has a market cap of $17.61 billion, a P/E ratio of 25.70, a P/E/G ratio of 1.86 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The company had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. During the same period last year, the business earned $2.31 EPS. Zimmer Biomet’s quarterly revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Sell-side analysts anticipate that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is presently 27.12%.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president directly owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. This represents a 20.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.39% of the company’s stock.

Institutional Investors Weigh In On Zimmer Biomet

A number of institutional investors and hedge funds have recently bought and sold shares of ZBH. Brighton Jones LLC purchased a new stake in Zimmer Biomet in the 4th quarter valued at $204,000. Sivia Capital Partners LLC purchased a new stake in Zimmer Biomet in the 2nd quarter valued at $232,000. United Bank raised its position in Zimmer Biomet by 10.7% in the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock valued at $1,085,000 after buying an additional 1,153 shares during the last quarter. J.W. Cole Advisors Inc. raised its position in Zimmer Biomet by 14.0% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 3,906 shares of the medical equipment provider’s stock valued at $356,000 after buying an additional 481 shares during the last quarter. Finally, Korea Investment CORP raised its position in Zimmer Biomet by 12.5% in the 2nd quarter. Korea Investment CORP now owns 111,789 shares of the medical equipment provider’s stock valued at $10,196,000 after buying an additional 12,400 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.